

Patent Docket P1974R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Baldwin et al.

Serial No.: 10/658,482

Filed: September 9, 2003

For:

NOVEL COMPOSITIONS AND

METHODS FOR THE TREATMENT OF

IMMUNE RELATED DISEASES

Group Art Unit: 1645

Examiner: Not Yet Assigned

Confirmation No: 3368

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450 on

December 12, 2003

7.9. Mans

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

[] 37 CFR §1.97(c)

 by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Serial No.: 10/658,482 Filed: September 9, 2003

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

Serial No.: 10/658,482

Filed: September 9, 2003

Page 3

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted

GENENTECH, INC

Date: December 12-2003

David A. Carpenter, Ph.D.

Reg. No. 45,945

Telephone No. (650) 225-3733

Sheet	1	of	1	
SHEEL	_	. UI	_	

FORM	PTO-1	449 DEC 1 5 200	OFICE	U.S. Dept. of Commerce	1 1	Oocket No.		Serial					
			Patent and Trademark Office		P1974R1		10/658482						
LIST	OF DIS	CLOSURES CHARGO	APPLICANT			win et al.							
(Use several sheets if necessary)					1 "	Filing Date 09 Sep 2003			Group 1645				
				U.S. PATENT DOCUMENTS									
Examiner nitials		Document Number	Date	Name		Class	Subcla	ass	Filing	Date			
	1	5,364,934	15.11.94	Drayna et al.									
	_			FOREIGN PATENT DOCUMENT	TS		-						
Examiner nitials		Document Number	Date	Country		Class Subo		ass	Transla Yes	tion No			
	2	WO01/75166	11.10.01	PCT									
				OSURES (Including Author, Title, Date									
	Bolton, C., "Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment." Multiple Sclerosis. 1:143-149 (1995)												
	4	Coligan et al, eds., "Proliferative Assays for T Cell Function" <u>Current Protocols in Immunology</u> , John Wiley & Sons, Inc., Chapter 3.12, Vol. 1 (1991)											
	5	Coligan et al., eds., "Delayed-Type Hypersensitivity." <u>Current Protocols in Immunology.</u> , New York: John Wiley & Sons, Inc., Chapter 4.5, (1994)											
	6	Issekutz et al., "Treatment of Established Adjuvant Arthritis in Rats with Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-Lymphocyte Migration to the Joints and Improves Clinical Disease." Immunology. 88:569-576 (1996)											
	7	Nickoloff et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model" Am. J. Path. 146(3):580-588 (1995)											
								•					
					-								
					,								
								·					
								,					
					*								
Examiner	L				Date Cons	idered							
*Examine	er: Initia	al if reference considermance and not consi	red, whether or no	t citation is in conformance with MPEF	609; dra	w line through	h citatio	n					